MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies
10 Julho 2023 - 9:05AM
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and
commercialization of next-generation cell-based therapeutics and to
support innovative, cell-based research, and Vittoria
Biotherapeutics (Vittoria), a leading edge, gene-edited cell
therapeutics company with novel platform technologies poised to
develop a pipeline of highly differentiated cellular therapies for
both oncology and immunology indications, today announced the
signing of a strategic platform license (SPL) of MaxCyte’s Flow
Electroporation® technology and ExPERT™ platform to Vittoria
Biotherapeutics.
Under the terms of the agreement, Vittoria will obtain
non-exclusive clinical and commercial rights to use MaxCyte’s Flow
Electroporation® technology and ExPERT™ platform. In return,
MaxCyte is entitled to receive platform licensing fees and
program-related revenue.
Vittoria’s technology and clinical programs are designed to
address current gaps with contemporary cell therapies and the
Company is planning to file an investigational new drug application
(IND) for their lead program, Viper 101, later this year. Viper 101
is a gene-edited, autologous, dual-population cell therapy
developed from Vittoria’s proprietary Senza5™ platform that
addresses significant unmet therapeutic need for the treatment of
T-cell lymphoma. Vittoria’s patent-protected Senza5™ platform
technology is designed to improve the viability, efficacy, and
safety of CAR-T treatments by modulating a novel checkpoint pathway
in engineered T-cells. Senza5™ CAR-T cells have demonstrated
superior anti-tumor efficacy in both liquid and solid tumor
preclinical models and utilize a proprietary five-day manufacturing
process.
“Working with partners to produce best-in-class solutions that
accelerate the development of novel therapies to improve patient
outcomes is central to our company’s mission” said Doug
Doerfler, President and Chief Executive Officer of
MaxCyte. “Through our partnership with Vittoria, MaxCyte
has gained an opportunity to further validate and showcase our
technology in a real-world setting and expand its footprint in the
promising field of CAR-T therapies. We look forward to supporting
Vittoria’s efforts to improve efficacy and enhance safety of T-cell
therapies.”
“At Vittoria, our goal is to deliver next-generation T-cell
therapies designed to improve patient outcomes by enhancing
the overall clinical utility and safety of engineered cell
therapies,” said Nicholas Siciliano, Ph.D., Chief Executive
Officer of Vittoria. “MaxCyte's experience with clinical
grade manufacturing of gene-edited cellular therapeutics will
greatly enhance the robustness and reproducibility of our
manufacturing process, ensuring that each batch of our CAR-T cells
meets the highest standards of consistency and quality. This is an
important step forward as we work to develop the next generation of
cellular therapies to benefit patients.”
MaxCyte’s ExPERT™ instrument portfolio is the next generation of
leading, clinically validated electroporation technology for
complex and scalable cell engineering. By delivering high
transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT™ platform delivers the high-end
performance essential to enabling the next wave of biological and
cellular therapeutics. Vittoria is MaxCyte’s 22nd SPL overall.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize
the potential of cells to improve patients’ lives. We have spent
more than 20 years honing our expertise by building best-in-class
platforms, perfecting the art of the transfection workflow, and
venturing beyond today’s processes to innovate tomorrow’s
solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. By providing our
partners with the right technology, as well as technical and
regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com and follow us on
Twitter and LinkedIn.
About Vittoria Biotherapeutics
Vittoria Biotherapeutics, Inc. (https://vittoriabio.com) is a
leading edge, gene-edited cell therapy company with novel platform
technologies exclusively licensed from the University of
Pennsylvania. Vittoria’s technology and clinical programs are
designed to address current gaps with contemporary cell therapies
and its pipeline benefits from access to novel gene editing
technologies. The Company is on track to file an IND in mid-2023
for their lead program, Viper 101. Viper 101 is a gene-edited,
autologous, dual-population cell therapy that addresses a
significant unmet therapeutic need for the treatment of T-cell
lymphoma. Vittoria’s gene-edited platform technology has
demonstrated superior anti-tumor efficacy in both liquid and solid
tumor preclinical models and utilizes a proprietary “short” (5-day)
manufacturing process. To learn more, visit vittoriabio.com and
follow us on LinkedIn.
MaxCyte Contacts:
US IR AdviserGilmartin GroupDavid
Deuchler, CFA+1 415-937-5400ir@maxcyte.com |
US Media RelationsSpectrum Seismic
CollaborativeValerie Enes+1
408-497-8568valerie@spectrumscience.com |
Nominated Adviser and
Joint Corporate BrokerPanmure GordonEmma
Earl / Freddy CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886
2500 |
UK IR
AdviserConsilium Strategic
CommunicationsMary-Jane ElliottChris Welsh+44 (0)203 709
5700maxcyte@consilium-comms.com |
Vittoria Contacts:
Investor Contact |
Media Relations |
Vittoria Biotherapeutics |
LifeSci Communications |
Nicholas A. Siciliano, Ph.D. |
Michael Tattory |
Chief Executive Officer |
+1 609-802-6265 |
+1 215-600-1380 |
mtattory@lifescicomms.com |
nsiciliano@vittoriabio.com |
|
MaxCyte (NASDAQ:MXCT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
MaxCyte (NASDAQ:MXCT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024